$2.78
0.010.36%
Ult. Agg.: Nov 6, 4:00 PM
The average analyst price target for Neuphoria Therapeutics is $35, 1159.0% above the current price. Of 2 analysts, 1 rates it Buy and 1 Hold. The latest change came on May 15, 2026, when HC Wainwright & Co. downgraded Neuphoria Therapeutics from Buy to Neutral.
Price Target Range — 3 Quarters
Analyst Consensus — 2 Analysts
Rating Trend — Last 9 Months